Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,436,966 papers from all fields of science
Search
Sign In
Create Free Account
STEAP1 gene
Known as:
SIX-TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE
, Six Transmembrane Epithelial Antigen of the Prostate 1 Gene
, STEAP1
Expand
This gene plays a role at cell-cell junctions.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Metalloreductase STEAP1
Oxidation-Reduction
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract LB-106: Allorepertoire-derived HLA class I/peptide-specific T cell receptor transgenic CD4+T cells mediate antitumor responses in Ewing sarcoma mimicking allo-rejection
S. J. Schober
,
M. Thiede
,
+5 authors
S. Burdach
Immunology
2018
Corpus ID: 81332013
Introduction: Innovative therapies are urgently warranted to cure patients with advanced Ewing sarcoma (ES). Specific cellular…
Expand
2016
2016
Isolation and purification of STEAP1 protein fragment in Escherichia coli cells: a potential target for prostate cancer
J. Ferreira
2016
Corpus ID: 104334326
2016
2016
Biosynthesis and isolation of STEAP1 protein from Escherichia coli cells lysates
J. Pais
2016
Corpus ID: 91987464
2015
2015
STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC).
D. Danila
,
M. Fleisher
,
+17 authors
O. Kabbarah
2015
Corpus ID: 78663625
5029 Background: STEAP1 is overexpressed in mCRPC and is an ADC target. STEAP1 expression in tissue assayed by IHC, protein and…
Expand
2015
2015
Abstract 5258: Expression analysis of STEAP1 in breast cancer patients as therapeutic target
Chidananda Mudalagiriyappa
,
S. Pillai
,
M. Watson
,
R. Aft
2015
Corpus ID: 78777362
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Objective: The six transmembrane epithelial…
Expand
2014
2014
Abstract 2069: Initial PET imaging and pharmacokinetic results from a Phase I/II study of Zr-89-labeled anti-STEAP1 antibody in metastatic castrate-resistant prostate cancer (mCRPC) patients
J. Carrasquillo
,
D. Danila
,
+14 authors
M. Morris
2014
Corpus ID: 70719716
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: STEAP1 (Six Transmembrane Epithelial Antigen…
Expand
2013
2013
A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).
D. Danila
,
R. Szmulewitz
,
+9 authors
U. Vaishampayan
2013
Corpus ID: 201181210
5020 Background: Six-transmembrane epithelial antigen of the prostate-1 (STEAP1) protein is a cell-surface antigen overexpressed…
Expand
2011
2011
Cancer Genes and Genomics STEAP 1 Is Associated with the Invasive and Oxidative Stress Phenotype of Ewing Tumors
T. Grunewald
,
I. Diebold
,
+16 authors
S. Burdach
2011
Corpus ID: 1171611
Ewing tumors comprise the second most common type of bone-associated cancer in children and are characterized by oncogenic EWS…
Expand
2009
2009
STEAP 4 regulates focal adhesion kinase activation and CpG motifs within STEAP 4 promoter region are frequently methylated in DU 145 , human androgen-independent prostate cancer cells
T. Tamura
,
J. Chiba
2009
Corpus ID: 38820710
The possible roles of STEAP4 in cancer progression have not been reported. In this study, we report that STEAP4 expression is…
Expand
2005
2005
Candidates for Prostate Cancer Immunotherapy Six-Transmembrane Epithelial Antigen of Prostate-3 as Human CTL Epitopes Prostatic Acid Phosphatase-3 and Updated
A. Machlenkin
,
A. Paz
,
+6 authors
L. Eisenbach
2005
Corpus ID: 14406143
Specific immunotherapy of prostate cancer may be an alternative or be complementary to other approaches for treatment of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE